RESUMEN
OBJECTIVE: To undertake an economic analysis of the Take Charge intervention as part of the Taking Charge after Stroke (TaCAS) study. DESIGN: An open, parallel-group, randomised trial comparing active and control interventions with blinded outcome assessment. SETTING: Community. PARTICIPANTS: Adults (n = 400) discharged to community, non-institutional living following acute stroke. INTERVENTIONS: The Take Charge intervention, a strengths based, self-directed rehabilitation intervention, in two doses (one or two sessions), and a control intervention (no Take Charge sessions). MEASURES: The cost per quality-adjusted life year (QALY) saved for the period between randomisation (always post hospital discharge) and 12 months following acute stroke. QALYs were calculated from the EuroQol-5D-5L. Costs of stroke-related and non-health care were obtained by questionnaire, hospital records and the New Zealand Ministry of Health. RESULTS: One-year post hospital discharge cost of care was mean (95% CI) $US4706 (3758-6014) for the Take Charge intervention group and $6118 (4350-8005) for control, mean (95% CI) difference $ -1412 (-3553 to +729). Health utility scores were mean (95% CI) 0.75 (0.73-0.77) for Take Charge and 0.71 (0.67-0.75) for control, mean (95% CI) difference 0.04 (0.0-0.08). Cost per QALY gained for the Take Charge intervention was $US -35,296 (=£ -25,524, -30,019). Sensitivity analyses confirm Take Charge is cost-effective, even at a very low willingness-to-pay threshold. With a threshold of $US5000 per QALY, the probability that Take Charge is cost-effective is 99%. CONCLUSION: Take Charge is cost-effective and probably cost saving.
Asunto(s)
Calidad de Vida , Accidente Cerebrovascular , Adulto , Análisis Costo-Beneficio , Humanos , Años de Vida Ajustados por Calidad de Vida , Encuestas y CuestionariosRESUMEN
OBJECTIVE: To use secondary data from the Taking Charge after Stroke study to explore mechanisms for the positive effect of the Take Charge intervention on physical health, advanced activities of daily living and independence for people after acute stroke. DESIGN: An open, parallel-group, randomised trial with two active and one control intervention and blinded outcome assessment. SETTING: Community. PARTICIPANTS: Adults (n = 400) discharged to community, non-institutional living following acute stroke. INTERVENTIONS: One, two, or zero sessions of the Take Charge intervention, a self-directed rehabilitation intervention which helps a person with stroke take charge of their own recovery. MEASURES: Twelve months after stroke: Mood (Patient Health Questionnaire-2, Mental Component Summary of the Short Form 36); 'ability to Take Charge' using a novel measure, the Autonomy-Mastery-Purpose-Connectedness (AMP-C) score; activation (Patient Activation Measure); body mass index (BMI), blood pressure (BP) and medication adherence (Medication Adherence Questionnaire). RESULTS: Follow-up was near-complete (388/390 (99.5%)) of survivors at 12 months. Mean age (SD) was 72.0 (12.5) years. There were no significant differences in mood, activation, 'ability to Take Charge', medication adherence, BMI or BP by randomised group at 12 months. There was a significant positive association between baseline AMP-C scores and 12-month outcome for control participants (1.73 (95%CI 0.90 to 2.56)) but not for the Take Charge groups combined (0.34 (95%CI -0.17 to 0.85)). CONCLUSION: The mechanism by which Take Charge is effective remains uncertain. However, our findings support a hypothesis that baseline variability in motivation, mastery and connectedness may be modified by the Take Charge intervention.
Asunto(s)
Afecto , Motivación , Rehabilitación de Accidente Cerebrovascular , Accidente Cerebrovascular/psicología , Actividades Cotidianas , Anciano , Presión Sanguínea , Índice de Masa Corporal , Femenino , Humanos , Masculino , Cumplimiento de la Medicación , Calidad de VidaRESUMEN
The estrogen receptor (ER) is a key predictive biomarker in the treatment of breast cancer. There is uncertainty regarding the use of hormonal therapy in the setting of weakly positive ER by immunohistochemistry (IHC). We report intrinsic subtype classification on a cohort of ER weakly positive early-stage breast cancers. Consecutive cases of breast cancer treated by primary surgical resection were retrospectively identified from 4 centers that engage in routine external proficiency testing for breast biomarkers. ER-negative (Allred 0 and 2) and ER weakly positive (Allred 3-5) cases were included. Gene expression profiling was performed using qRT-PCR. Intrinsic subtype prediction was made based upon the PAM50 gene expression signature. 148 cases were included in the series: 60 cases originally diagnosed as ER weakly positive and 88 ER negative. Of the cases originally assessed as ER weakly positive, only 6 (10 %) were confirmed to be of luminal subtype by gene expression profiling; the remaining 90 % of cases were classified as basal-like or HER2-enriched subtypes. This was not significantly different than the fraction of luminal cases identified in the IHC ER-negative cohort (5 (5 %) luminal, 83(95 %) non-luminal). Recurrence-free, and overall, survival rates were similar in both groups (p = 0.4 and 0.5, respectively) despite adjuvant hormonal therapy prescribed in the majority (59 %) of weakly positive ER cases. Weak ER expression by IHC is a poor correlate of luminal subtype in invasive breast cancer. In the setting of highly sensitive and robust IHC methodology, cutoffs for ER status determination and subsequent systemic therapy should be revisited.
Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias de la Mama/genética , Recurrencia Local de Neoplasia/genética , Receptores de Estrógenos/genética , Adulto , Anciano , Biomarcadores de Tumor/biosíntesis , Neoplasias de la Mama/clasificación , Neoplasias de la Mama/patología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Estimación de Kaplan-Meier , Persona de Mediana Edad , Invasividad Neoplásica/genética , Invasividad Neoplásica/patología , Recurrencia Local de Neoplasia/patología , Pronóstico , Receptor ErbB-2/biosíntesis , Receptor ErbB-2/genética , Receptores de Estrógenos/biosíntesis , Receptores de Progesterona/genética , TranscriptomaRESUMEN
BACKGROUND AND PURPOSE: "Take Charge" is a novel, community-based self-directed rehabilitation intervention which helps a person with stroke take charge of their own recovery. In a previous randomized controlled trial, a single Take Charge session improved independence and health-related quality of life 12 months following stroke in Maori and Pacific New Zealanders. We tested the same intervention in three doses (zero, one, or two sessions) in a larger study and in a broader non-Maori and non-Pacific population with stroke. We aimed to confirm whether the Take Charge intervention improved quality of life at 12 months after stroke in a different population and whether two sessions were more effective than one. METHODS: We randomized 400 people within 16 weeks of acute stroke who had been discharged to institution-free community living at seven centers in New Zealand to a single Take Charge session (TC1, n = 132), two Take Charge sessions six weeks apart (TC2, n = 138), or a control intervention (n = 130). Take Charge is a "talking therapy" that encourages a sense of purpose, autonomy, mastery, and connectedness with others. The primary outcome was the Physical Component Summary score of the Short Form 36 at 12 months following stroke comparing any Take Charge intervention to control. RESULTS: Of the 400 people randomized (mean age 72.2 years, 58.5% male), 10 died and two withdrew from the study. The remaining 388 (97%) people were followed up at 12 months after stroke. Twelve months following stroke, participants in either of the TC groups (i.e. TC1 + TC2) scored 2.9 (95% confidence intervals (CI) 0.95 to 4.9, p = 0.004) points higher (better) than control on the Short Form 36 Physical Component Summary. This difference remained significant when adjusted for pre-specified baseline variables. There was a dose effect with Short Form 36 Physical Component Summary scores increasing by 1.9 points (95% CI 0.8 to 3.1, p < 0.001) for each extra Take Charge session received. Exposure to the Take Charge intervention was associated with reduced odds of being dependent (modified Rankin Scale 3 to 5) at 12 months (TC1 + TC2 12% versus control 19.5%, odds ratio 0.55, 95% CI 0.31 to 0.99, p = 0.045). CONCLUSIONS: Confirming the previous randomized controlled trial outcome, Take Charge-a low-cost, person-centered, self-directed rehabilitation intervention after stroke-improved health-related quality of life and independence. CLINICAL TRIAL REGISTRATION-URL: http://www.anzctr.org.au. Unique identifier: ACTRN12615001163594.
Asunto(s)
Rehabilitación de Accidente Cerebrovascular , Accidente Cerebrovascular , Anciano , Femenino , Humanos , Masculino , Nueva Zelanda , Calidad de Vida , Centros de RehabilitaciónRESUMEN
BACKGROUND: Our aim was to identify the number of cases of secretory carcinoma (SC) of the major salivary gland in a population-based cohort and review its clinical behavior with long-term follow-up. METHODS: All malignant salivary gland tumors (MSGTs) diagnosed between 1980 and 2014 were assessed for histological features compatible with SC and 140 were selected for further analysis. RESULTS: Twenty two new cases of SC were identified, 19 of which were originally classified as acinic cell carcinoma, and 3 as adenocarcinoma, not otherwise specified (NOS). Lymph node involvement was less common in SC tumors (5%) than in the control group (11%). Disease recurrence was seen less frequently in SC (9%) than the control group (20%). Mean disease-free survival was 192 months for SC compared with 162 months for controls (P = 0.15). CONCLUSION: The clinical course of SC is typically indolent with a low risk of relapse not significantly different from other low-grade MSGT.
Asunto(s)
Carcinoma , Neoplasias de las Glándulas Salivales , Adenocarcinoma/epidemiología , Adenocarcinoma/patología , Adulto , Carcinoma/epidemiología , Carcinoma/patología , Carcinoma/terapia , Carcinoma de Células Acinares/epidemiología , Carcinoma de Células Acinares/patología , Estudios de Casos y Controles , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Sistema de Registros , Estudios Retrospectivos , Neoplasias de las Glándulas Salivales/epidemiología , Neoplasias de las Glándulas Salivales/patología , Neoplasias de las Glándulas Salivales/terapia , Análisis de SupervivenciaRESUMEN
BACKGROUND: Trastuzumab-based chemotherapy can improve median survival in the metastatic setting when used in patients with cancer that overexpresses HER2/neu. In addition to HER2 expression, other molecular markers are needed to better predict outcomes after the initiation of trastuzumab-based chemotherapy and to elucidate potential mechanisms of resistance to trastuzumab. PATIENTS AND METHODS: Patients with clinical documentation of HER2/neu-overexpressing metastatic breast cancer treated with trastuzumab between 1998 and 2004 were identified from the British Columbia Provincial Pharmacy Database. Tissues were obtained for microarray analysis of 153 of 306 patients who fit our clinical criteria. Tissue microarrays were constructed for the analysis of multiple molecular factors, and results were correlated to clinical outcomes. Immunohistochemistry was performed on the microarray specimens, and results were correlated with survival and time to progression. RESULTS: Factors commonly associated with poor prognosis in the metastatic setting in general, including short disease-free intervals, high tumor grade, and low estrogen receptor status, were all associated with poor survival in this population with HER2 overexpression. Overexpression of HER3 was observed in 9% of specimens and was associated with a trend toward worse overall survival (P = 0.1). HER3 expression was not correlated with a significant difference in time to progression but did trend to predict for worse survival after progression (P = 0.06). In multivariate analysis, tumor grade and HER3 expression were significantly predictive of overall survival. Phosphatase and tensin homologue status did not appear to correlate with response or survival. CONCLUSION: Our findings suggest that prognosis after initiation of trastuzumab-based chemotherapy depends, in part, on coexpression of HER3.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/mortalidad , Anticuerpos Monoclonales Humanizados , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Colombia Británica/epidemiología , Bases de Datos Factuales , Supervivencia sin Enfermedad , Femenino , Humanos , Inmunohistoquímica , Registros Médicos , Análisis por Micromatrices , Metástasis de la Neoplasia , Valor Predictivo de las Pruebas , Receptor ErbB-2/metabolismo , Estudios Retrospectivos , Análisis de Supervivencia , TrastuzumabRESUMEN
BACKGROUND: The reliability of fine-needle aspiration (FNA) biopsy in differentiating benign from malignant follicular lesions of the thyroid has been the subject of renewed debate recently. Although surgical excision has been recommended for most follicular lesions identified by cytology, this approach may not be necessary in all cases. The goal of this study was to determine whether FNA could be used as a diagnostic tool to safely identify patients with follicular thyroid nodules who do not require immediate surgical intervention. METHODS: A retrospective review was performed on a sample of 24 patients diagnosed with either follicular adenoma or follicular carcinoma after surgical excision of a thyroid nodule. The initial FNA biopsies were independently reviewed by two experienced cytopathologists in a blinded fashion and subsequently compared with final histologic diagnoses. RESULTS: For pathologist A, overall accuracy was 58%. The positive predictive value (PPV) of a benign diagnosis was 82%; PPV of a malignant diagnosis was 38%. For pathologist B, overall accuracy was 63%. The PPV of a benign diagnosis was 83%; PPV of a malignant diagnosis was 42%. CONCLUSIONS: This study suggests that in follicular lesions of the thyroid, a benign FNA biopsy report from an experienced cytopathologist has a high positive predictive value. The predictive value may not, however, be high enough to preclude surgery; other factors may need to be considered before recommending a nonoperative approach.
Asunto(s)
Adenoma/patología , Biopsia con Aguja Fina , Carcinoma/patología , Nódulo Tiroideo/patología , Adenoma/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/cirugía , Distribución de Chi-Cuadrado , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Sensibilidad y Especificidad , Nódulo Tiroideo/cirugíaRESUMEN
Rehabilitation in inpatient settings is expensive and staff-intensive. It is necessary for such services to demonstrate effectiveness to justify this. In contrast to popular notions, evidence for the effectiveness of inpatient rehabilitation does exist and is reviewed in this article. In particular, there is very good evidence for specialized inpatient stroke care and rehabilitation.
Asunto(s)
Hospitalización , Centros de Rehabilitación/normas , Anciano , Lesiones Encefálicas/rehabilitación , Fracturas del Fémur/rehabilitación , Anciano Frágil , Humanos , Pacientes Internos , Esclerosis Múltiple/rehabilitación , Traumatismos de la Médula Espinal/rehabilitación , Rehabilitación de Accidente CerebrovascularRESUMEN
Interphase fluorescence in situ hybridization (FISH) with chromosome 3 and 17 centromeric probes and DNA flow cytometry were used for a retrospective study of nine pediatric medulloblastomas with normal karyotypes after tissue culture. The FISH analysis of medulloblastoma touch preparations showed that in seven of nine tumors, a significant proportion of nuclei had an increased number of centromeric signals for the selected chromosomes. In six of seven cases, this increase was caused by the presence of triploid and tetraploid clones as established by flow cytometry of paraffin-embedded tumors. These findings show that molecular cytogenetic analysis combined with DNA flow cytometry is necessary for all pediatric medulloblastomas diagnosed as cytogenetically normal on cultured tumor tissue.
Asunto(s)
Neoplasias Cerebelosas/genética , Cromosomas Humanos Par 17 , Cromosomas Humanos Par 3 , ADN de Neoplasias/análisis , Meduloblastoma/genética , ADN de Neoplasias/genética , Citometría de Flujo , Humanos , Hibridación Fluorescente in Situ , CariotipificaciónAsunto(s)
Ataxia/fisiopatología , Infarto Encefálico/diagnóstico por imagen , Enfermedades Cerebelosas/diagnóstico por imagen , Fibrinolíticos/uso terapéutico , Cefalea/fisiopatología , Activador de Tejido Plasminógeno/uso terapéutico , Disección de la Arteria Vertebral/diagnóstico por imagen , Adulto , Ataxia/etiología , Infarto Encefálico/tratamiento farmacológico , Infarto Encefálico/fisiopatología , Enfermedades Cerebelosas/tratamiento farmacológico , Enfermedades Cerebelosas/fisiopatología , Cerebelo/irrigación sanguínea , Angiografía por Tomografía Computarizada , Cefalea/diagnóstico por imagen , Cefalea/etiología , Humanos , Masculino , Dolor de Cuello , Resultado del Tratamiento , Disección de la Arteria Vertebral/tratamiento farmacológico , Disección de la Arteria Vertebral/fisiopatologíaRESUMEN
AIMS: To examine whether stroke care processes and outcomes are improved following the institution of an acute stroke unit (ASU) at a medium-sized New Zealand hospital. METHODS: Two retrospective audits over 12-month periods were carried out at Hutt Valley Hospital before and after the institution of a 6-bed ASU. Data was collected on demographics, length of stay, stroke type, investigations, processes of care and outcomes. RESULTS: 139 strokes pre ASU and 155 strokes post ASU were studied. 86.8% of strokes received stroke unit care in the 2009 audit. There were more intracerebral haemorrhages in 2006 (17.2% vs. 9.0%). Significant improvements were seen between 2006 and 2009 in time to aspirin administration (52.7 versus 14.5 hours), swallow assessment within 24 hours (88.5% versus 96.1%), lag time to carotid Doppler studies (21 days versus 4.5 days), pressure risk assessments (19.6%, versus 87.2%) and urinary infection rates (10.8% versus 2.0% ). Total length of stay (TLOS) and mortality were reduced but the difference was not statistically significant. (20.5 days versus 18.3 days p=0.34, Inpatient mortality 16.2% versus 10% p=0.12). CONCLUSIONS: The introduction of an ASU has resulted in improvements in several key processes of stroke care. Overall mortality and total length of stay showed a trend to improvement after the establishment of an ASU.
Asunto(s)
Mortalidad Hospitalaria , Unidades Hospitalarias/organización & administración , Evaluación de Procesos y Resultados en Atención de Salud , Accidente Cerebrovascular/mortalidad , Accidente Cerebrovascular/terapia , Factores de Edad , Anciano , Distribución de Chi-Cuadrado , Estudios de Cohortes , Cuidados Críticos/organización & administración , Femenino , Hospitales Generales , Humanos , Tiempo de Internación , Masculino , Auditoría Médica , Nueva Zelanda , Grupo de Atención al Paciente/organización & administración , Mejoramiento de la Calidad , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Accidente Cerebrovascular/diagnóstico , Análisis de SupervivenciaRESUMEN
AIMS: The aim of this project was to employ interdepartmental and cross district health board collaboration to reach a regional consensus on the management of patients who may benefit from carotid endarterectomy. METHODS: All regional stroke physicians, neurologists, and vascular surgeons met to review relevant literature and local audits and to discuss best management strategies suited to the region. RESULTS: A consensus statement was agreed upon and is presented here along with a summary of the supporting scientific evidence. DISCUSSION: Regional interdisciplinary collaboration proved an effective way to reach a carotid endarterectomy management consensus across a wider geographical area that is served by a single vascular surgery department. This approach could serve as a model for other regional initiatives.
Asunto(s)
Estenosis Carotídea/cirugía , Endarterectomía Carotidea/normas , Accidente Cerebrovascular/prevención & control , Anticoagulantes/uso terapéutico , Puente de Arteria Coronaria , Diagnóstico por Imagen , Femenino , Humanos , Masculino , Nueva Zelanda , Selección de Paciente , Complicaciones Posoperatorias/prevención & controlRESUMEN
CONTEXT: The development of trastuzumab has led to new therapeutic strategies for patients with breast cancer. Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). OBJECTIVE: To determine the accuracy of HER2 testing in 2 provinces in Canada. DESIGN: Patients with metastatic breast cancer diagnosed between 1999 and 2002 who were HER2 positive in the local laboratories were included in this study. All cases were retested centrally, by IHC (using 4 methods) and FISH. In addition, 205 locally reported HER2-negative metastatic breast cancer cases were retested centrally. RESULTS: Concordance between the 505 local IHC-positive cases with central IHC testing varied between 79.3% and 89.6% depending on the IHC method and scoring method used. HER2 gene amplification by FISH was present in 86.1% of local IHC-positive cases. Concordance between the 205 local IHC-negative tumors with central testing ranged between 94.8% and 100% for IHC and was 98.5% for FISH. CONCLUSIONS: This study demonstrated that locally reported HER2-negative results were highly accurate, but less accuracy was demonstrated with local HER2-positive results. These results emphasize the need for participation in a quality assurance program.